Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by BTC Capital Management Inc.

BTC Capital Management Inc. lowered its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 24.4% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 53,655 shares of the biopharmaceutical company’s stock after selling 17,282 shares during the quarter. BTC Capital Management Inc.’s holdings in Gilead Sciences were worth $4,956,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. nVerses Capital LLC bought a new position in Gilead Sciences during the 3rd quarter valued at $25,000. Valued Wealth Advisors LLC increased its holdings in Gilead Sciences by 101.9% in the third quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 161 shares during the last quarter. Decker Retirement Planning Inc. acquired a new position in shares of Gilead Sciences in the 4th quarter worth approximately $29,000. Crews Bank & Trust bought a new stake in shares of Gilead Sciences in the 4th quarter valued at approximately $31,000. Finally, Strategic Investment Solutions Inc. IL bought a new position in Gilead Sciences during the second quarter worth $33,000. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Gilead Sciences Price Performance

Shares of GILD stock opened at $96.95 on Friday. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $98.90. The company has a market capitalization of $120.83 billion, a P/E ratio of 1,077.22, a P/E/G ratio of 1.34 and a beta of 0.18. The stock has a 50 day moving average of $92.28 and a two-hundred day moving average of $85.59. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, topping the consensus estimate of $1.58 by $0.44. The firm had revenue of $7.55 billion during the quarter, compared to analysts’ expectations of $7.01 billion. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. During the same period last year, the business earned $2.29 earnings per share. Gilead Sciences’s quarterly revenue was up 7.0% compared to the same quarter last year. As a group, equities analysts expect that Gilead Sciences, Inc. will post 4.36 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the stock. Barclays boosted their target price on shares of Gilead Sciences from $84.00 to $95.00 and gave the company an “equal weight” rating in a research note on Thursday, November 7th. Leerink Partners upgraded shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and increased their price objective for the stock from $74.00 to $96.00 in a research note on Monday, October 21st. Daiwa America upgraded Gilead Sciences to a “hold” rating in a research note on Monday, November 18th. Sanford C. Bernstein began coverage on Gilead Sciences in a research report on Thursday, October 17th. They set an “outperform” rating and a $105.00 price target on the stock. Finally, BMO Capital Markets boosted their price objective on Gilead Sciences from $94.00 to $102.00 and gave the company an “outperform” rating in a research report on Thursday, November 7th. Eleven investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and four have issued a strong buy rating to the stock. According to data from MarketBeat.com, Gilead Sciences has an average rating of “Moderate Buy” and a consensus target price of $98.39.

Insiders Place Their Bets

In other news, CFO Andrew D. Dickinson sold 2,500 shares of the firm’s stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $91.35, for a total value of $228,375.00. Following the transaction, the chief financial officer now owns 129,873 shares of the company’s stock, valued at approximately $11,863,898.55. This trade represents a 1.89 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Jeffrey Bluestone sold 6,788 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $91.39, for a total transaction of $620,355.32. Following the sale, the director now owns 8,920 shares of the company’s stock, valued at approximately $815,198.80. This represents a 43.21 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 456,234 shares of company stock valued at $42,130,461. 0.16% of the stock is currently owned by insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.